What if the path to treating a rare condition that harms the brain goes through the liver? A new study by Duke University School of Medicine researchers is the first to show preclinical success of a liver targeting treatment of glutaric aciduria type I (GA1).
GA1 is a rare, inherited metabolic disorder linked to the inability to properly break down the essential amino acid lysine. In childhood, this deficiency can lead to the buildup of toxic byproducts in the brain. This is believed to be the main culprit of irreversible neurological damage, in particular to areas of the brain responsible for motor function, associated with GA1.
Every newborn child in the United States is screened for GA1. Current standard of care includes a low lysine diet, and emergency interventions for acute neurological illness. But, because there is no specific therapy, about a third of patients develop severe movement disorders and some complications can be fatal.
A team led by Duke pediatrics researcher Karl-Dimiter Bissig, MD, PhD , used small interfering RNA (siRNA) to silence a gene involved in the breakdown of lysine. The study was published November 18 in Science Translational Medicine, and is a collaboration between Duke, University of Colorado Anschutz, and Alnylam Pharmaceuticals.
The researchers showed that delivering their siRNA therapy to adult mouse models kept them all alive and treated neonatal mouse models survived better than the control group – even while on high protein diets.
"What we have now is a translational approach," said senior author Bissig, Chen Family Associate Professor of Pediatrics. "It gives us hope."
The researchers also inspected tissues of the treated mice and found significant reduction in metabolic byproducts, including in the brain – which did not suffer injury in treated mice. Sorting through these tissues also led to the discovery that blood plasma harbored metabolic biomarkers that predicted neurological outcomes, pointing to a new avenue for therapeutic monitoring.
This investigation builds on previous work by Bissig and collaborators, who in 2023 showed that the toxic metabolites causing brain damage were produced in the liver and crossed the blood-brain barrier. Identifying the liver as the origin of this condition was a paradigm shift for the field.
"There are these connections within the body, particularly through metabolism," said Bissig. "The liver is connected with every single organ." Using the analogy of wired versus wireless internet connections, Bissig sees the brain as hardwired to parts of the body through neurons while the liver is connected to other organs wirelessly through circulating metabolites.
Bissig hopes to continue this work into clinical trials. With siRNA being a nonpermanent approach to genetic therapy and multiple siRNA drugs targeting the liver already on the market, Bissig believes the siRNA approach could provide a smooth pathway to market.
It would also be a gamechanger for patients who currently have to strictly monitor their diet. "You could inject patients 2 or 3 times a year, and they're protected 24-7," said Bissig. "Imagine how easy that therapy could be."
Other Duke authors: Yunhan Ma, Maiya Fujiwara, Haoyue Zhang, James Beasley, Ashley Stiles, Sarah Young, Areeg El-Gharbawy, Mercedes Barzi, Beatrice Bissig-Choisat.
Funding: The Alice and Y. T. Chen Center for Genetics and Genomics, sponsored research agreement with Alnylam Pharmaceuticals, National Institute of Diabetes and Digestive and Kidney Disease, National Institute of Child Health and Human Development, Duke Cancer Institute
Citation: "Rescue of glutaric aciduria type I by GalNAc-conjugated siRNA against aminoadipate semialdehyde synthase". Yunhan Ma et al. Science Translational Medicine, 2026. DOI: 10.1126/scitranslmed.aej2067